We are developing a treatment modality that uses the oral immune system to deliver a biologic (IgG) to calm an overactive immune system. High dose Intravenous Immunoglobulin (IVIG) has a long history of successful clinical use to treat autoimmune, infectious and idiopathic diseases. However, our OroMucosal ImmunoGlobulin (OMIG) patch uses up to 1000X less immunoglobulin allowing more patients to be served with less active agent. The OMIGPatch™ is non-invasive and may provide a better safety profile in some instances since systemic exposure to IgG is limited.
Our first indication is COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) in which we plan to file an Emergency Use Authorization application with the US FDA.